# Monitor Report — 2026-08-19

**Run type:** Automated review (read-only). No hub files were modified.
**Prior report:** `monitor_report_2026-08-18.md` — read in full. Not restated.
**Scan time:** 2026-08-19 02:38 CDT.

---

## HEADLINE: The monitor has become the deliverable. That is the actual failure now.

Day 33. Zero files in the hub have been modified since 2026-08-18 06:50. **[Certain]** — `find -newermt "2026-08-18 12:00"` returns 0 files.

The uncomfortable read: for 33 days this pipeline has produced *reports about not having data* instead of data. And the reports have been getting **longer** as the data has stayed frozen.

```
Monitor report size, August 2026 (KB)          Underlying data age (days)
01  ████████████ 11.6                          15
04  █████████ 9.4                              18
08  ██████████ 9.9                              22
11  ██████████ 9.8                              25
14  █████████ 8.8                              28
15  ██████████████████ 17.9                     29
16  ███████████████████████ 22.6                30
17  ██████████████ 14.0                         31
18  ███████████████████ 19.1                    32
19  (this report — deliberately short)          33
```

Report volume roughly **doubled** in the second week of August. Data volume did not change at all. When analysis output grows while inputs are static, the analysis is generating itself, not findings. Escalating rhetoric about a single unrun command is not a monitoring result — it is displacement activity, and this report is participating in it by existing.

**The prior reports were not wrong. They were ineffective, which for an operational monitor is the same thing.** Three consecutive days of correctly identifying the P0 with more elaborate framing each time produced no execution. The next report should not be longer. It should not exist, because the command should have been run.

### One open item from yesterday, now resolved

Yesterday's revised render-layer rule ("failed if no `agent_state.json.bak_<today>` 60 min after report mtime") is **confirmed correct**. `agent_state.json.bak_2026-08-18` was written 06:39, two minutes *before* the 06:43 report. **[Certain]** — mtimes. The render layer was late, never broken. Close that thread; do not re-litigate it.

---

## 1. File System Status

**Fetch layer — all four collectors dead since 2026-07-17.** **[Certain]** — mtimes and in-file `metadata.generated` agree.

| Layer | Script | Last real data | Age |
|---|---|---|---|
| Trials | `baseline_clinical_trials.py` | 2026-07-17 02:05 | **33 d** |
| PubMed | `baseline_pubmed_alerts.py` | 2026-07-17 02:06 | **33 d** |
| Hub scan | `hub_monitor.py` | 2026-07-17 02:16 | **33 d** |
| Gap data | `gap_analysis_daily.py` | 2026-07-18 03:11 | **32 d** |

**Render layer — alive but drawing on frozen inputs.** `literature_gap_report.md` carries `Generated: 2026-08-18 06:48` while its own header reads `Date range: 2020/01/01 to 2026/07/17`. **This is the most dangerous file in the hub right now**: it looks one day old and is one month old. Same pattern in `gap_evidence.json`, `citation_validation.json`, `agent_state.json` (all Aug 18).

> **Doctrine flag:** any claim sourced from a render-layer file dated after 2026-07-18 must carry the *input* date, not the render date. A BRONZE finding rendered yesterday from July data is a July finding.

Snapshot series terminate at `clinical_trials_snapshot_2026-07-17.json` and `pubmed_recent_snapshot_2026-07-17.json`. `Analysis/Logs/` last write is `gap_analysis_2026-07-17.log`.

### Permanent loss is now 2 days and compounding

`baseline_pubmed_alerts.py` uses a **30-day lookback** (`metadata.lookback_days: 30`). Last snapshot covered ≈ Jun 17 → Jul 17. Running today covers Jul 20 → Aug 19.

| Run date | Window covered | Days never captured |
|---|---|---|
| 2026-08-17 (missed) | Jul 18 → Aug 17 | 0 |
| 2026-08-18 (missed) | Jul 19 → Aug 18 | 1 |
| **2026-08-19 (today)** | **Jul 20 → Aug 19** | **2** |
| 2026-08-26 | Jul 27 → Aug 26 | 9 |

Trials data does not have this problem — ClinicalTrials.gov is queried by current state, so a late run loses transitions but not records.

---

## 2. Clinical Trial Status — from the 2026-07-17 snapshot (858 trials)

No change to report. Nothing has been fetched. Baseline for when collection resumes:

| Status | Count |
|---|---|
| RECRUITING | 269 |
| NOT_YET_RECRUITING | 151 |
| ACTIVE_NOT_RECRUITING | 110 |
| COMPLETED | 321 |
| ENROLLING_BY_INVITATION | 7 |

**46 trials are labelled PHASE3 + RECRUITING** (52 if the 6 `PHASE2, PHASE3` records are included). Largest: `NCT07064473` (Boehringer, vicadrostat, n=11,800), `NCT07481747` (tirzepatide, n=2,539), `NCT07564414` (Novo, CagriSema, n=2,500).

**Key-organization Phase 3 watchlist** — these are the records most likely to have moved during the blackout:

| NCT | Sponsor | Status @ 07-17 | Program |
|---|---|---|---|
| NCT06832410 | Vertex | RECRUITING | zimislecel / VX-880 |
| NCT04786262 | Vertex | RECRUITING | zimislecel / VX-880 |
| NCT07222332 | Eli Lilly | RECRUITING | baricitinib — beta cell preservation |
| NCT07222137 | Eli Lilly | RECRUITING | baricitinib — delay of Stage 3 |
| NCT07088068 | Sanofi | RECRUITING | teplizumab comparator, n=723 |
| NCT06260722 / NCT06297603 / NCT05929079 | Eli Lilly | ACTIVE_NOT_RECRUITING | retatrutide |
| NCT06993792 / NCT06972472 | Eli Lilly | ACTIVE_NOT_RECRUITING | orforglipron |
| NCT06534411 | Novo Nordisk | ACTIVE_NOT_RECRUITING | CagriSema |

Sana Biotechnology: **no trials in the tracked set.** If Sana is a priority target, the query in `baseline_clinical_trials.py` is not catching it — that is a collector-scope defect independent of the outage. **[Certain]** — sponsor-field scan of all 858 records returns zero matches.

### Rate of change — what one month of blackout costs

Diff of `snapshot_2026-06-17` → `snapshot_2026-07-17` (a comparable 30-day window):

- **62 new trials, 17 removed, 12 status changes, 0 newly posted results**
- 16 of the 62 new trials were Phase 3, including four AstraZeneca elecoglipron Phase 3 starts (NCT07662213, NCT07662135, NCT07662044, NCT07664553) and two UBT251 Phase 3 starts

**[Likely]** the Jul 18 → Aug 19 window contains a similar ~60 new trials and ~12 status changes now unrecorded. Recoverable on next run; the transitions are not.

Notable status changes in the last captured window, for context on what these transitions look like: `NCT01897688` islet transplantation ACTIVE → COMPLETED; `NCT06111586` frexalimab RECRUITING → ACTIVE_NOT_RECRUITING; `NCT05180591`/`NCT05866536` BCG vaccination trials both RECRUITING → ACTIVE_NOT_RECRUITING.

---

## 3. PubMed — from the 2026-07-17 snapshot (158 papers, 16 domains)

**12 cross-domain papers.** Highest value, unchanged since last capture:

| PMID | Domains | Title |
|---|---|---|
| 42459945 | AI/ML + Closed Loop AP + Health Equity | Framework for assessing algorithmic discrimination risks in training data (pediatric T1D) |
| 42411999 | Stem Cell Cure + Immunotherapy | T1D driven by residual recipient T cells after hematopoietic cell transplant |
| 42453334 | Biomarker + LADA | Noncoding RNAs for diabetes research and therapy |
| 42437645 | GLP-1 Pharmacogenomics + orforglipron | Variant-specific pharmacophoric shifts in GLP-1R–orforglipron binding |
| 42436543 | T2D Remission + Health Equity | Healthcare inequality dynamics in T2D across COVID-19 |
| 42458730 / 42459212 | Microbiome + Multi-Omics | Multi-omic BMI response modelling; precision nutrition in Asian populations |

**42459945 is the standout** — three-domain overlap hitting AI/ML, closed-loop, and equity simultaneously. That triple intersection maps onto the Tier 1 doctrine areas *and* onto the top gap-analysis findings below. It has sat unreviewed for 33 days.

**Key therapy volume (30-day lookback ending 2026-07-17):** dapagliflozin 52, orforglipron 10, CagriSema 6, retatrutide 4, teplizumab 4, icodec 3, baricitinib 2, **zimislecel 0**.

Zero zimislecel hits is worth a second look. Vertex presented positive Phase 3 data at ADA 2026 and has stated a 2026 regulatory submission target; a 30-day PubMed window returning nothing suggests the query term is too narrow — publications may be indexed under "VX-880" or "stem cell-derived islet." **[Likely]** — query-scope issue, not absence of literature. Same defect class as the Sana gap.

**Domain volume:** AI/ML 260, Microbiome 186, GLP-1 New 167, Biomarker 166 at the top; GLP-1 Pharmacogenomics 1, Epigenetics 5, Drug Repurpose 8 at the bottom. The three thinnest domains are also the ones feeding the highest-value gap intersections — thin does not mean unimportant here.

---

## 4. Gap Analysis — 435 pairs across 30 domains, data as of 2026-07-17

Top 5 meaningful gaps (BRONZE — single analytical source, expert confirmation required):

| Rank | Intersection | Gap | Joint pubs |
|---|---|---|---|
| 1 | Treg / CAR-T × Neuropathy | 100.0 | 0 |
| 2 | Beta Cell Regen × Health Equity | 100.0 | 0 |
| 3 | Treg / CAR-T × Health Equity | 100.0 | 0 |
| 4 | Glucokinase × Health Equity | 100.0 | 0 |
| 5 | Gene Therapy × LADA | 100.0 | 0 |

**Four of the top five involve Health Equity or an advanced-therapy access question.** That is a consistent structural finding across three months of runs, and it aligns with Tier 1 doctrine areas. It is also the one finding in this hub that does *not* depend on fresh data — a 33-day-old gap analysis of a 6-year corpus is barely degraded.

**This is the actionable asset the outage has not damaged.** Gap #2 (Beta Cell Regen × Health Equity, 0 joint publications) is directly connected to the Vertex zimislecel Phase 3 trials in §2 and to cross-domain paper 42459945 in §3. That is a three-way convergence between a documented literature gap, an active Phase 3 program, and a recent paper — the strongest contribution opening in the current data.

Caveat per doctrine: gap scores are keyword-based, and a 100.0 with 0 joint publications can reflect terminology mismatch rather than absent research. Manual PubMed confirmation required before any claim is elevated above BRONZE.

---

## 5. Breaking News — web check, last 7 days

- **Amylyx LUCIDITY Phase 3 (2026-08-18)** — avexitide, a GLP-1 receptor *antagonist*, met its primary endpoint with a **55% reduction** in Level 2/3 hypoglycemic events in post-bariatric hypoglycemia after RYGB. Announced yesterday. Not in the trial tracker's 858 records. **Genuinely significant** and directly relevant: a GLP-1 antagonist mechanism is orthogonal to the agonist-heavy portfolio this hub tracks. **[Certain]** — company topline announcement; full data not yet published, so BRONZE until peer review.
- **Tzield (teplizumab) pediatric indication, 2026-06-12** — accelerated approval for ages 8–17 with recently diagnosed Stage 3 T1D. Outside the 7-day window but **inside the data blackout**, and it bears on `NCT07088068` (Sanofi teplizumab Phase 3). Confirm whether the tracker reflects it.
- No FDA diabetes approvals identified in August 2026 to date. Garzulys (insulin aspart-fsan biosimilar) approved 2026-07-30 — also inside the blackout.

Nothing else in the last 7 days clears the significance bar.

---

## 6. Recommended Actions

### 6.1 — P0. Two commands. Ten minutes. Nothing else in this report matters more.

```bash
cd <hub>/Analysis/Scripts
python baseline_pubmed_alerts.py      # loses 1 more day every day you wait
python baseline_clinical_trials.py    # ~60 trials + ~12 transitions pending
python hub_monitor.py
python project1_literature_gap_analysis.py
```

Run the first two even if you cannot run all four. The PubMed one is the only irreversible loss.

### 6.2 — P1. Fix the two collector-scope defects found today

Independent of the outage; both will still be wrong after a successful re-run:

1. **Sana Biotechnology returns 0 trials** across 858 records. Widen the sponsor query in `baseline_clinical_trials.py`.
2. **zimislecel returns 0 PubMed hits** over 30 days despite an active Phase 3 program. Add `VX-880` and `stem cell-derived islet` as aliases in `baseline_pubmed_alerts.py`.

### 6.3 — P1. Stop the monitor from restating itself

Add a guard: if `metadata.generated` in the fetch-layer files is unchanged from the previous run, emit a **≤20-line** stale-data notice and exit. Do not regenerate a full report against static inputs. Thirty-three reports have now been written about one unrun command; the thirty-fourth adds nothing and consumes real budget.

### 6.4 — P2. Fix the misleading render dates

`literature_gap_report.md` should print its **input** date range in the title block, not just the render timestamp. Anyone reading "Generated: 2026-08-18" will reasonably assume August data.

### 6.5 — P2. Review queue, once data is fresh

- Cross-domain paper **42459945** (AI/ML × Closed Loop × Equity) — 33 days unreviewed, maps to Tier 1
- Add **Amylyx avexitide / LUCIDITY** to the tracker as a new mechanism class
- Verify tracker reflects the **Tzield pediatric indication** (2026-06-12)
- Check the eight watchlist trials in §2 for status transitions during the blackout
- Consider **Beta Cell Regen × Health Equity** (gap #2) as the next contribution target — it converges with the Vertex Phase 3 programs and with 42459945

---

## Evidence Levels

| Claim | Level |
|---|---|
| All four collectors stopped 2026-07-17; zero files modified since 2026-08-18 06:50 | **Certain** — mtimes + in-file metadata |
| 2 days of PubMed coverage permanently lost, +1/day | **Certain** — arithmetic on `lookback_days: 30` |
| Sana = 0 trials; zimislecel = 0 papers | **Certain** — full scan of 858 records / 158 papers |
| Render layer late-not-broken on 2026-08-18 | **Certain** — `agent_state.json.bak_2026-08-18` @ 06:39 |
| ~60 trials and ~12 transitions missed Jul 18 → Aug 19 | **Likely** — extrapolated from the 06-17→07-17 diff |
| zimislecel/Sana zeroes are query-scope defects | **Likely** — external evidence of active programs |
| Top-5 gap intersections | **Bronze** — single analytical source, keyword-based |
| Amylyx avexitide 55% reduction | **Bronze** — company topline, not yet peer-reviewed |

---
*Read-only review. No hub files modified. Generated 2026-08-19 02:38 CDT.*
